![DYNAVAX TECHNOLOGIES DYNAVAX TECHNOLOGIES](/cache/medias/logo_company/150x80-thumb/D48l032gglBtsDu.webp?v=4)
Eröffnung: | - |
Veränderung: | - |
Volumen: | - |
Tief: | - |
Hoch: | - |
Hoch - Tief: | - |
Typ: | Aktien |
Ticker: | DVAX |
ISIN: |
Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2022 Conference
- 63
PR Newswire
EMERYVILLE, Calif., Jan. 5, 2022
EMERYVILLE, Calif., Jan. 5, 2022 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect 2022 Conference being held January 10-13, 2022.
The on demand presentation will be available, beginning Monday, January 10, 2022 at 7:00 a.m. E.T. and may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at http://investors.dynavax.com/events-presentations.
About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines to help protect the world against infectious diseases. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, plague, Tdap, seasonal influenza and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.
Contacts:
Nicole Arndt
[email protected]
510-665-7264
Derek Cole, President
Investor Relations Advisory Solutions
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-virtual-bioconnect-2022-conference-301454785.html
SOURCE Dynavax Technologies
![](https://rt.prnewswire.com/rt.gif?NewsItemId=SF22624&Transmission_Id=202201051605PR_NEWS_USPR_____SF22624&DateId=20220105)